SIO Far Rockaway is now open! | Cedarhurst Physical Therapy location is now open!


Garrett Moss, MD

Dr. Moss recently returned to South Island Orthopedics after five years as the Director of Adult Reconstruction at Catholic Health Services of Long Island Mercy Medical Center. Although he grew up in Boulder, Colorado, Dr. Moss is a native of New York, and has been a practicing orthopedic surgeon since completing his fellowship at Columbia University Medical Center in New York City. 

Dr. Moss holds bachelor’s degrees in chemical engineering and economics from the University of Pennsylvania, as well as an MBA from Harvard Business School. He earned his medical degree from Columbia University College of Physicians and Surgeons, and completed his residency at Mount Sinai Hospital in New York City. 

When he’s not seeing patients, Dr. Moss is a long-distance runner and has completed several marathons, as well as an Ironman Triathlon in Lake Placid, NY. He also spends time keeping up with his active family, including catching some waves in the Rockaways as well as exploring the vineyards and wineries of eastern Long Island.

Education & Training

  • COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS, New York, NY. Doctor of Medicine (MD). Graduated May 2007. Clinical honors in Surgery, Orthopaedic surgery, Pediatrics, Urology, Psychiatry.
OF BUSINESS ADMINISTRATION, Boston, MA. Master in Business Administration degree, June 1999. Graduated with distinction. Recipient of HBS Junior Achievement Teaching Scholarship.
  • UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA. Bachelor of Science in Chemical Engineering, magna cum laude. Bachelor of Science in Economics, Wharton School of Business, magna cum laude, with concentration in finance. Recipient of Senior Award for Chemical Engineering. Varsity Track Team

Internship and Residency

  • THE MOUNT SINAI HOSPITAL, New York, NY. 2006-2012, Department of Orthopaedic Surgery. NYS License obtained 2008


  • COLUMBIA UNIVERSITY MEDICAL CENTER, New York, NY. 2012-2013, Clinical Fellow, Center for Hip and Knee Replacement


    Research Assistant, Department of Surgery. Conducted cardiothoracic research in Dr. Mehmet’s Oz’s lab.
    • Managed basic research project measuring ability of cytokine inhibitors to reduce inflammation of heart tissue following damage from myocardial infarction. Research included performing coronary artery ligations for rat model of heart failure, and analyzing echocardiograms and hemodynamic data.
    • Participated as member of transplant team, being on call once a week for heart/lung harvests.
  • 1999-200: MCKINSEY & COMPANY, New York, NY. Associate, Management Consulting. Participated in general management consulting team, focusing on pharmaceutical and surgical device companies.
  • 1996-1997: EXXON CHEMICAL CORPORATION, Elizabeth, NJ. Chemical Engineer. Worked on chemical plant division of refinery, responsible for overall product quality, capital improvement projects, and throughput for engine oil unit of operations.


  • 2006-2007 ST. VINCENT’S HOSPITAL, Volunteer, Pre-Health Rotation Program. Participated in eighteen-month program consisting of fifteen separate rotations in various departments at St. Vincent’s, obtaining clinical exposure.
  • 2005-present INTERNATIONAL RESCUE COMMITTEE, Member, Junior Benefits Council. Organized and participated in committee fundraising events.

Personal Interests include marathon running, golf, and basketball. Instrument-rated airplane pilot.


  • Grelsamer R, Moss GW, Donell S. The patellofemoral pain syndrome: pathophysiology and nomenclature. Knee, Oct 2009, 16(5):301-2.
  • Moss GW, Kherani R, Zhou H, Burkhoff D, Oz, M, et al. Macrophage Inhibitor, Semapinod, Reduces Tumor Necrosis Factor-Alpha in Myocardium in a Rat Model of Ischemic Heart Failure, Journal of Cardiovascular Pharmacology, Vol. 44, Issue 6, Dec. 2004.
  • Xydas S, Kherani R, Moss GW, Oz M, Wang J, et al. β2 Adrenergic Stimulation Attenuates Left Ventricular Remodeling, Decreases Apoptosis, and Improves Calium Homeostasis in a Rodent Model of Ischemic Cardiomyopathy, Journal of Pharmacology and Experimental Therapeutics, January 2006, 317:553-561.